Kansas Polycystic Kidney Imaging Program

堪萨斯州多囊肾成像计划

• 批准号: 8710152
• 负责人: Alan S Yu
• 金额: $ 27.13万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-02-01 至 2016-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8710152
• 关键词: Address; Affect; Age; Alabama; Ancillary Study; Autosomal Dominant Polycystic Kidney; Biological; Biological Markers; Characteristics; Clinic; Clinical; Clinical Data; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Counseling; Cyst; Cystic kidney; DNA; Data; Data Analyses; Development; Diet; Disease Progression; End stage renal failure; Family member; Funding; Genetic; Genotype; Goals; Growth; Hepatic Cyst; Image; Individual; Intake; Intervention; Intervention Studies; Kansas; Kidney; Kidney Diseases; Kidney Failure; Life Expectancy; Liver; Magnetic Resonance; Magnetic Resonance Imaging; Measurement; Methods; Modeling; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Other Genetics; Participant; Patient Outcomes Assessments; Patients; Pattern; Phenotype; Pilot Projects; Polycystic Kidney Diseases; Population; Predictive Value; Principal Investigator; Proteomics; Quality of life; Renal Blood Flow; Renal function; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Sensitivity and Specificity; Severities; Severity of illness; Sodium; Surrogate Markers; Testing; Universities; Washington; base; follow-up; genetic risk factor; improved; kidney imaging; modifiable risk; programs; repository; serological marker; sex; urinary; Address; Affect; Age; Alabama; Ancillary Study; Autosomal Dominant Polycystic Kidney; Biological; Biological Markers; Characteristics; Clinic; Clinical; Clinical Data; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Counseling; Cyst; Cystic kidney; DNA; Data; Data Analyses; Development; Diet; Disease Progression; End stage renal failure; Family member; Funding; Genetic; Genotype; Goals; Growth; Hepatic Cyst; Image; Individual; Intake; Intervention; Intervention Studies; Kansas; Kidney; Kidney Diseases; Kidney Failure; Life Expectancy; Liver; Magnetic Resonance; Magnetic Resonance Imaging; Measurement; Methods; Modeling; Morbidity - disease rate; National Institute of Diabetes and Digestive and Kidney Diseases; Nature; Other Genetics; Participant; Patient Outcomes Assessments; Patients; Pattern; Phenotype; Pilot Projects; Polycystic Kidney Diseases; Population; Predictive Value; Principal Investigator; Proteomics; Quality of life; Renal Blood Flow; Renal function; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Sensitivity and Specificity; Severities; Severity of illness; Sodium; Surrogate Markers; Testing; Universities; Washington; base; follow-up; genetic risk factor; improved; kidney imaging; modifiable risk; programs; repository; serological marker; sex; urinary

DESCRIPTION (provided by applicant): Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of morbidity and the fourth leading cause of ESRD in the world, affecting more than 500,000 U.S. citizens. Researchers at the University of Alabama, Emory University, University of Kansas, Mayo Clinic and Washington University joined together in 2000 to create the Consortium for Radiologic Studies of Polycystic Kidney Disease (CRISPI) and in 2006 included the University of Pittsburgh in place of Washington University for CRISP II. The primary objectives of CRISPI and II were to: establish accurate, reliable and reproducible magnetic resonance based measurements of total kidney volume (TKV), liver cyst volume (LCV), renal blood flow (RBF), and patterns of cyst growth and expansion. Based on 7.3 years of longitudinal followup in 200 CRISP l/ll participants, we can now: 1) establish an unequivocal relationship between TKV and qualitative (patient reported outcomes) and quantitative (renal insufficiency) end-points; as well as 2) identify potential modifiable risk factors associating with TKV and LCV for intervention studies. TKV ultimately may be used as a surrogate marker of disease progression in clinical trials. The goals of CRISPIN extend the observations of CRlSPI/ll. The overarching Aim for CRISP III is to develop and enhance prediction models that best predict renal insufficiency in ADPKD. Specifically, Aim 1: Extend the serial quantification of TKV and LCV to develop and test new models for predicting the risk of developing renal insufficiency. Aim 2: Determine the extent to which age and sex-adjusted measurements of RBF predict the rate of change in TKV and determine if RBF and TKV independently predict the risk of developing renal insufficiency. Aim 3: Develop methods to quantify the influence of renal cyst number, volume, and topography at baseline on the subsequent course of TKV and GFR and the risk of developing renal insufficiency. Aim 4: Expand and analyze CRISP biological samples collected in NIDDK repositories to improve genotype/phenotype and biomarker studies, and facilitate ancillary studies. Aim 5: Test the feasibility and efficacy of intensive dietary counseling in modifying the fixed pattern of sodium intake observed in CRISP and determine if this change alters the rate of TKV change.

描述（由申请人提供）：常染色体显性多囊性肾脏疾病（ADPKD）是世界上ESRD的第四个主要原因，影响了50万以上美国公民。阿拉巴马大学，埃默里大学，堪萨斯大学，梅奥诊所和华盛顿大学的研究人员于2000年共同创建了多囊肾脏病放射学研究联盟（CRISPI），并于2006年包括华盛顿大学匹兹堡大学的匹兹堡大学，以供克里斯普II。 CRISPI和II的主要目标是：建立基于总肾脏体积（TKV），肝囊肿体积（LCV），肾血流（RBF）以及囊肿生长和膨胀模式的准确，可靠和可再现的磁共振测量。基于200个Crisp L/LL参与者的7。3年的纵向随访，我们现在可以：1）在TKV与定性（患者报告的结果）和定量（肾功能不全）终点之间建立明确的关系；以及2）确定与TKV和LCV相关的潜在可修改风险因素进行干预研究。在临床试验中，TKV最终可以用作疾病进展的替代标志。克里斯平的目标扩展了CRLSPI/LL的观察结果。 Crisp III的总体目的是开发和增强预测模型，以最能预测ADPKD的肾脏不足。具体而言，目标1：扩展对TKV和LCV的串行量化，以开发和测试新模型，以预测肾脏不足的风险。 AIM 2：确定RBF的年龄和性别调整后的测量程度可以预测TKV的变化率，并确定RBF和TKV是否独立预测肾脏不足的风险。 AIM 3：开发方法来量化基线时肾脏囊肿数，体积和地形的影响对TKV和GFR的随后过程，以及肾功能不全的风险。目标4：扩展和分析NIDDK存储库中收集的清晰生物样品，以改善基因型/表型和生物标志物研究，并促进辅助研究。 AIM 5：测试密集饮食咨询的可行性和功效，以修改Crisp中观察到的固定钠摄入量的固定模式，并确定这种变化是否改变了TKV变化的速度。